Teegan A. Dellibovi-Ragheb
FDA investigator
Appears on 1 document from 2023, mostly at sites in Maryland. Most often cites written procedures; deviations (21 CFR 211.100).
- 1
- Documents on file
- 6.0
- Observations per 483
- 2023
- First seen
- 2023
- Most recent
What they cite most
From 6 observations- 21 CFR 211.100Written procedures; deviations1
- 21 CFR 211.110Sampling and testing of in-process materials and drug products1
- 21 CFR 211.113Control of microbiological contamination1
- 21 CFR 211.188Batch production and control records1
- 21 CFR 211.192Production record review1
- 21 CFR 211.25Personnel qualifications1
Activity by year
2023: 1
Where
Maryland 1
Often inspects with
Is Teegan A. Dellibovi-Ragheb coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2023-12-11 | 483 Human Genome Sciences, Inc.Dec 11, 2023 · Rockville, Maryland | Rockville, Maryland | 6 |
About this profile
What does Teegan A. Dellibovi-Ragheb inspect?
Teegan A. Dellibovi-Ragheb appears on 1 document on file covering 1 site, mostly in Maryland.
What do they cite most often?
21 CFR 211.100 (written procedures; deviations), followed by 21 CFR 211.110 and 21 CFR 211.113.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Teegan A. Dellibovi-Ragheb is dated Dec 11, 2023.